+

WO2003013585A8 - Agonistes et antagonistes de la mifaxine convenant au traitement de troubles du metabolisme au moyen - Google Patents

Agonistes et antagonistes de la mifaxine convenant au traitement de troubles du metabolisme au moyen

Info

Publication number
WO2003013585A8
WO2003013585A8 PCT/IB2002/003545 IB0203545W WO03013585A8 WO 2003013585 A8 WO2003013585 A8 WO 2003013585A8 IB 0203545 W IB0203545 W IB 0203545W WO 03013585 A8 WO03013585 A8 WO 03013585A8
Authority
WO
WIPO (PCT)
Prior art keywords
mifaxin
agonists
antagonists
activity
metabolic
Prior art date
Application number
PCT/IB2002/003545
Other languages
English (en)
Other versions
WO2003013585A1 (fr
Inventor
John Lucas
Deno Dialynas
Kristen Briggs
Aaron Scalia
Original Assignee
Genset Sa
John Lucas
Deno Dialynas
Kristen Briggs
Aaron Scalia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset Sa, John Lucas, Deno Dialynas, Kristen Briggs, Aaron Scalia filed Critical Genset Sa
Publication of WO2003013585A1 publication Critical patent/WO2003013585A1/fr
Publication of WO2003013585A8 publication Critical patent/WO2003013585A8/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne, dans le domaine des recherches sur le métabolisme, la découverte de composés permettant de réduire la masse corporelle et convenant pour le traitement d'affections et troubles en lien avec l'obésité. Les affections et troubles en lien avec l'obésité que l'on envisage de traiter par les procédés de l'invention concernent notamment l'hyperlipémie l'athérosclérose, la résistance à l'insuline, les diabètes, et l'hypertension. L'invention concerne plus particulièrement des procédés permettant d'identifier et d'utiliser des agonistes et des antagonistes de l'activité mifaxine, l'activité mifaxine étant sélectionnée dans le groupe du partitionnement de lipides, le métabolisme des lipides, et l'activité de type insulinique.
PCT/IB2002/003545 2001-08-08 2002-08-06 Agonistes et antagonistes de la mifaxine convenant au traitement de troubles du metabolisme au moyen WO2003013585A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31151001P 2001-08-08 2001-08-08
US60/311,510 2001-08-08

Publications (2)

Publication Number Publication Date
WO2003013585A1 WO2003013585A1 (fr) 2003-02-20
WO2003013585A8 true WO2003013585A8 (fr) 2003-04-17

Family

ID=23207219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/003545 WO2003013585A1 (fr) 2001-08-08 2002-08-06 Agonistes et antagonistes de la mifaxine convenant au traitement de troubles du metabolisme au moyen

Country Status (1)

Country Link
WO (1) WO2003013585A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033134B8 (fr) * 1997-10-29 2007-09-19 Otsuka Pharmaceutical Co., Ltd. Compositions inhibant la proliferation des muscles lisses et procede de diagnostic de l'arteriosclerose
EP1085897A4 (fr) * 1998-05-21 2003-03-12 Smithkline Beecham Corp Acrp30r1l, homologue de acrp30 (proteine associee a un complement de l'adipocyte 30 kd)
JP2002542771A (ja) * 1999-03-24 2002-12-17 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒト腫瘍壊死因子レセプターｔｒ９
EP1177296A2 (fr) * 1999-05-11 2002-02-06 Incyte Genomics, Inc. Proteines de matrice extracellulaire associees a l'adhesion
WO2000073448A1 (fr) * 1999-05-27 2000-12-07 Zymogenetics, Inc. Homologue zacrp7 de proteine lie a un complement adipocyte
ATE405655T1 (de) * 2000-01-14 2008-09-15 Serono Genetics Inst Sa Obg3 globularekopf und seine verwendungen zur reduzierung des körpersgewichtes

Also Published As

Publication number Publication date
WO2003013585A1 (fr) 2003-02-20

Similar Documents

Publication Publication Date Title
HUS1600042I1 (hu) Anti-CS1 antitestek terápiás alkalmazása
WO2004110376A3 (fr) Antagonistes de ccr-2 permettant de traiter une douleur neuropathique
WO2005102387A3 (fr) Utilisation therapeutique des anticorps anti-cs1
WO2004047760A3 (fr) Nouveaux composes chimiques
WO2004056307A3 (fr) Traitement de maladie par le biais d'inhibiteurs de peptides antimicrobiens
BR0315598A (pt) Anticorpos neutralizantes contra gdf-8 e usos dos mesmos
WO2003057698A3 (fr) Composes spiroazacycliques utilises comme modulateurs du recepteur de monoamine
WO2005030240A3 (fr) Produits vegf-c ou vegf-d et methodes de stimulation des cellules souches neurales
EP1251126A3 (fr) Derives de benzenesulfonyle a substitution fluor pour le traitment d'inflammation
PL378026A1 (pl) Leczenie chorób z zastosowaniem pełnych agonistów receptora Ó-7 nACh
AU2002258428A1 (en) Methods for the treatment of metabolic disorders, including obesity and diabetes
AU2003299378A1 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
WO2001092330A3 (fr) Utilisation de tete globulaire acrp30 afin de developper l'augmentation de la masse musculaire et de la differentiation musculaire
WO2006047759A3 (fr) Inhibiteurs de kinase destines au traitement du diabete et de l'obesite
WO2003013578A8 (fr) Traitement des troubles metabolique au moyen d'agonistes et d'antagonistes d'omoxine
WO2003013585A8 (fr) Agonistes et antagonistes de la mifaxine convenant au traitement de troubles du metabolisme au moyen
WO2003013604A3 (fr) Traitement des troubles metaboliques par les agonistes et les antagonistes de migenix
WO2003050281A3 (fr) Polynucleotides et polypetides gzip et leurs utilisations
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
WO2005070042A3 (fr) Nouveaux composes chimiques
WO2007067516A3 (fr) Myelome multiple
WO2003095485A3 (fr) Polynucleotides et polypeptides krib et utilisations de ceux-ci dans le traitement de troubles metaboliques
WO2003030936A1 (fr) Medicaments contre des maladies liees au style de vie ou la cibophobie et methode de criblage de ces derniers
WO2003033534A3 (fr) Polynucleotides et polypeptides ngzipa, ngzipd, pgzipa et pgzipd et utilisations de ceux-ci
WO2004053107A3 (fr) Methodes de traitement du diabete

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载